Study shows liraglutide results in increased insulin sensitivity independent of

Examine reveals liraglutide ends in elevated insulin sensitivity unbiased of weight reduction

Study shows liraglutide results in increased insulin sensitivity independent of weight loss
Graphical summary. Credit score: Diabetes (2023). DOI: 10.2337/db23-0356

A current examine revealed within the journal Diabetes demonstrates {that a} glucagon-like peptide-1 receptor (GLP-1R) agonist, a member of a category of treatment used to deal with sort 2 diabetes and weight problems, can result in a speedy enchancment in insulin sensitivity.

Insulin sensitivity is how responsive cells are to insulin, a necessary hormone that controls blood glucose ranges. A rise in insulin sensitivity means insulin can extra successfully decrease blood glucose. Diminished insulin sensitivity or insulin resistance is a function of sort 2 diabetes. Thus, improved insulin sensitivity can scale back the chance of creating sort 2 diabetes or enhance its therapy.

GLP-1R agonists are drugs that affect metabolism, similar to lowering blood sugar ranges by selling insulin secretion. Dipeptidyl peptidase 4 (DPP-4) inhibitors block the degradation of the physique’s personal endogenous GLP-1, in addition to different peptide hormones similar to glucose-dependent insulinotropic peptide (GIP).

“We all know that GLP-1R agonists promote weight reduction, however we had been shocked to seek out that the GLP-1R agonist liraglutide additionally has speedy results on insulin sensitivity, unbiased from weight reduction,” mentioned Mona Mashayekhi MD, Ph.D., assistant professor of Medication within the Division of Diabetes, Endocrinology and Metabolism. “This impact requires activation of the GLP-1 receptor, however rising the physique’s personal endogenous GLP-1 by way of using the DPP4 inhibitor sitagliptin doesn’t obtain related results.”

“Our analysis means that liraglutide, and presumably different GLP-1R agonists, are having vital metabolic results in a manner that is completely different from rising endogenous GLP-1 ranges, despite the fact that they’re utilizing the identical receptor. Future analysis will concentrate on potential mechanisms of how GLP-1R agonists are bettering insulin sensitivity unbiased of weight reduction.”

Eighty-eight people with weight problems and pre-diabetes had been randomized for 14 weeks to obtain the GLP-1R agonist liraglutide, the dipeptidyl peptidase 4 (DPP-4) inhibitor sitagliptin, or weight reduction with out drug utilizing a low-calorie food regimen.

To additional examine the GLP-1R-dependent results of the remedies, the GLP-1R antagonist exendin and a placebo got in a two-by-two crossover examine throughout blended meal checks. Crossover research permit the response of a topic to therapy A to be in contrast with the identical topic’s response to therapy B.

Liraglutide was proven to quickly enhance insulin sensitivity in addition to lower blood glucose inside two weeks of starting therapy and earlier than any weight reduction.

“GLP-1R agonists are an thrilling class of medicines, given their robust glucose-lowering results mixed with large weight-loss advantages, they usually have reworked how we handle diabetes and weight problems within the clinic,” Mashayekhi mentioned. “Because the variety of drugs on this class is quickly increasing, a deeper understanding of the mechanisms of profit is essential so we will design the appropriate medication for the specified results in the appropriate sufferers.”

The investigators’ prior analysis demonstrated that liraglutide, however not sitagliptin or food regimen, improves measures of coronary heart illness and irritation. This matches the medical findings of decreased heart problems with GLP-1R agonist therapy.

Future research will proceed to discover each receptor- and weight loss-dependent results of GLP-1R agonists in people.

Extra data:
Mona Mashayekhi et al, Weight Loss–Unbiased Impact of Liraglutide on Insulin Sensitivity in People With Weight problems and Prediabetes, Diabetes (2023). DOI: 10.2337/db23-0356

Offered by
Vanderbilt College Medical Middle

Examine reveals liraglutide ends in elevated insulin sensitivity unbiased of weight reduction (2024, January 4)
retrieved 5 January 2024

This doc is topic to copyright. Aside from any honest dealing for the aim of personal examine or analysis, no
half could also be reproduced with out the written permission. The content material is offered for data functions solely.

Add a Comment

Your email address will not be published. Required fields are marked *